Friday, June 14, 2019

DNA repair deficiency in neuropathogenesis: when all roads lead to mitochondria

›
Luis Bermúdez-Guzmán and Alejandro Leal; Translational Neurodegeneration 20198:14 doi:10.1186/s40035-019-0156-x Diseases such as Friedreic...
Thursday, June 13, 2019

Prominent Spasticity and Hyperreflexia of the Legs in a Nepalese Patient with Friedreich At

›
Hiroya Naruse, Yuji Takahashi, Hiroyuki Ishiura, Takashi Matsukawa, Jun Mitsui, Yaeko Ichikawa, Masashi Hamada, Jun Shimizu, Jun Goto, Tatsu...
Wednesday, June 12, 2019

Frataxin deficiency induces lipid accumulation and affects thermogenesis in brown adipose tissue

›
Riccardo Turchi, Flavia Tortolici, Giulio Guidobaldi, Federico Iacovelli, Mattia Falconi, Stefano Rufini, Raffaella Faraonio, Viviana Casagr...
Tuesday, June 11, 2019

Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates

›
Reisman SA, Gahir SS, Lee CY, Proksch JW, Sakamoto M, Ward KW (Reata Pharmaceuticals, Inc., Irving, TX 75063, USA); Drug Des Devel Ther. 201...

Is left ventricular longitudinal strain a good prognostic factor in Friedreich ataxia?

›
C. Heuze, L. Legrand, A. Diallo, M.L. Monin, C. Ewenczyk, R. Isnard, E. Vicaut, A. Durr, F. Pousset, Archives of Cardiovascular Diseases Sup...
Friday, June 7, 2019

Microvascular pathology in Friedreich cardiomyopathy

›
Arnulf H. Koeppen, Jiang Qian, Alicia M. Travis, Alyssa B. Sossei, Paul J. Feustel and Joseph E. Mazurkiewicz; Histol Histopathol. 2019 Jun ...
Wednesday, June 5, 2019

Minoryx inicia el primer tratamiento de un paciente con Ataxia de Friedreich en el Hospital La Paz

›
Mataró (Barcelona)-Charleroi (Bélgica), 4 de mayo de 2019. Minoryx Therapeutics, compañía biotecnológica especializada en el desarrollo de n...

Minoryx Therapeutics enrôle le premier patient de son essai clinique de phase II dans l’ataxie de Friedreich

›
Mataró, Barcelone, Espagne et Charleroi, Belgique, le 4 juin 2019 - Minoryx Therapeutics, une société spécialisée dans le développemen...

Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia

›
Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that the first patient has...
Tuesday, June 4, 2019

Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich’s Ataxia

›
Mittal Jasoliya , Francesco Sacca , Sunil Sahdeo, Frederic Chedin, Chiara Pane, Vincenzo Brescia Morra, Alessandro Filla, Mark Pook, Gino Co...